Organon & Co (OGN) - Net Assets
Based on the latest financial reports, Organon & Co (OGN) has net assets worth $903.00 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.00 Billion) and total liabilities ($12.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OGN goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $903.00 Million |
| % of Total Assets | 6.95% |
| Annual Growth Rate | -26.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 68.56 |
Organon & Co - Net Assets Trend (2018–2025)
This chart illustrates how Organon & Co's net assets have evolved over time, based on quarterly financial data. See Organon & Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Organon & Co (2018–2025)
The table below shows the annual net assets of Organon & Co from 2018 to 2025. For live valuation and market cap data, see OGN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $752.00 Million | +59.32% |
| 2024-12-31 | $472.00 Million | +774.29% |
| 2023-12-31 | $-70.00 Million | +92.15% |
| 2022-12-31 | $-892.00 Million | +40.85% |
| 2021-12-31 | $-1.51 Billion | -127.49% |
| 2020-12-31 | $5.49 Billion | -22.02% |
| 2019-12-31 | $7.04 Billion | +10.82% |
| 2018-12-31 | $6.35 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Organon & Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 110900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.11 Billion | 147.47% |
| Common Stock | $3.00 Million | 0.40% |
| Other Comprehensive Income | $-527.00 Million | -70.08% |
| Other Components | $167.00 Million | 22.21% |
| Total Equity | $752.00 Million | 100.00% |
Organon & Co Competitors by Market Cap
The table below lists competitors of Organon & Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stride Inc
NYSE:LRN
|
$3.52 Billion |
|
Shenzhen Hopewind Elec Co Ltd
SHG:603063
|
$3.52 Billion |
|
HARBOUR ENE.SP.ADR LS-50
F:PQQ2
|
$3.52 Billion |
|
GEK TERNA Holdings Real Estate Construction S.A
AT:GEKTERNA
|
$3.53 Billion |
|
Korn Ferry
NYSE:KFY
|
$3.52 Billion |
|
Suzhou UIGreen Micro & Nano Technologies Co. Ltd. A
SHG:688661
|
$3.52 Billion |
|
INDIVIOR PLC DL 050
F:2IVB
|
$3.51 Billion |
|
Amcor plc
F:485
|
$3.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Organon & Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 472,000,000 to 752,000,000, a change of 280,000,000 (59.3%).
- Net income of 187,000,000 contributed positively to equity growth.
- Dividend payments of 88,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 122,000,000.
- Other factors increased equity by 59,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $187.00 Million | +24.87% |
| Dividends Paid | $88.00 Million | -11.7% |
| Other Comprehensive Income | $122.00 Million | +16.22% |
| Other Changes | $59.00 Million | +7.85% |
| Total Change | $- | 59.32% |
Book Value vs Market Value Analysis
This analysis compares Organon & Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.54x to 4.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $25.08 | $13.43 | x |
| 2019-12-31 | $27.79 | $13.43 | x |
| 2020-12-31 | $21.64 | $13.43 | x |
| 2021-12-31 | $-5.95 | $13.43 | x |
| 2022-12-31 | $-3.50 | $13.43 | x |
| 2023-12-31 | $-0.27 | $13.43 | x |
| 2024-12-31 | $1.82 | $13.43 | x |
| 2025-12-31 | $2.88 | $13.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Organon & Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.01%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 17.11x
- Recent ROE (24.87%) is below the historical average (40.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 33.92% | 22.02% | 0.93x | 1.65x | $1.52 Billion |
| 2019 | 45.74% | 41.38% | 0.74x | 1.50x | $2.51 Billion |
| 2020 | 39.37% | 33.07% | 0.65x | 1.84x | $1.61 Billion |
| 2021 | 0.00% | 21.43% | 0.59x | 0.00x | $1.50 Billion |
| 2022 | 0.00% | 14.85% | 0.56x | 0.00x | $1.01 Billion |
| 2023 | 0.00% | 16.33% | 0.52x | 0.00x | $1.03 Billion |
| 2024 | 183.05% | 13.49% | 0.49x | 27.76x | $816.80 Million |
| 2025 | 24.87% | 3.01% | 0.48x | 17.11x | $111.80 Million |
Industry Comparison
This section compares Organon & Co's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $9,072,978,101
- Average return on equity (ROE) among peers: 25.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Organon & Co (OGN) | $903.00 Million | 33.92% | 13.39x | $3.52 Billion |
| AbbVie Inc (ABBV) | $17.29 Billion | 68.47% | 7.03x | $356.49 Billion |
| Amgen Inc (AMGN) | $1.91 Billion | 35.66% | 0.45x | $181.97 Billion |
| Amarin Corporation PLC (AMRN) | $-202.37 Million | 0.00% | 0.00x | $315.59 Million |
| AstraZeneca PLC (AZN) | $23.25 Billion | 10.99% | 1.40x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $169.87 Million | 71.43% | 35.43x | $271.29 Billion |
| Biogen Inc (BIIB) | $74.90 Million | -25.50% | 0.15x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $11.85 Billion | 8.50% | 1.83x | $110.27 Billion |
| Gilead Sciences Inc (GILD) | $4.47 Billion | 44.31% | 0.55x | $153.55 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $28.44 Billion | 20.21% | 2.87x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $3.48 Billion | 23.90% | 0.88x | $550.26 Billion |
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more